Navigation Links
BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones
Date:1/10/2014

160; BDSI plans to initiate a Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy in the first quarter of 2014.   This study could complete enrollment in late 2014.
  • Re-launch of ONSOLIS.  BDSI continues to work closely with its commercial partner, Meda Pharmaceuticals, on plans for the reintroduction of ONSOLIS into the U.S. market for the management of breakthrough pain in opioid tolerant patients with cancer.  This is anticipated to take place in the second half of 2014.
  • About BioDelivery Sciences International

    BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

    BDSI's pain franchise currently consists of three products.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BEMA Buprenorphine, which is licensed on a worldwide basis to Endo Pharmaceuticals, is currently in Phase 3 development for the treatment of moderate to severe chronic pain.  Clonidine Topical Gel is expected to enter Phase 3 trials in 2014 for the treatment of painful diabetic neuropathy.

    BUNAVAIL, a BEMA formulation of
    '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
    2. BioDelivery Sciences to Present at the 25th Annual Piper Jaffray Healthcare Conference
    3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials
    4. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
    5. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
    6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
    7. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
    8. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
    9. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
    10. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
    11. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
    (Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
    (Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
    Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
    ... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
    ... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
    Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
    (Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
    (Date:7/12/2014)... (PRWEB) July 12, 2014 Praeclarus ... Made Simple as a valuable new resource for women ... two-thirds of American women work away from their children. ... touting the benefits of breastfeeding, but often feel unsupported ... nurse their babies. With its evidence-based insights, and written ...
    (Date:7/12/2014)... Augusta, GA (PRWEB) July 12, 2014 ... Nova Medical Centers, is pleased to announce that it ... , This new facility will join four Atlanta-based ... will be located at 3209 Deans Bridge Road, and ... Monday through Friday. , “With Nova’s treatment philosophy ...
    (Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
    (Date:7/11/2014)... 2014 (HealthDay News) -- People with the lowest incomes may ... artery disease (PAD), a new study suggests. People with ... the limbs, most often the legs. The condition causes leg ... arteries throughout the body. People with PAD have a higher ... from nearly 6,800 people with PAD who took part in ...
    Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2
    ... with effects of prescription drugs for heart troubles, researcher says ... of Americans who are taking traditional herbal medications for heart ... new report says. , "They may be safe," said Dr. ... Arizona, and author of a report in the Feb. 9 ...
    ... ... ability to convert into a stylish, comfortable footrest , ... Las Vegas (PRWEB) February 1, 2010 -- ... Chair® Recliners and other wellness solutions, announced today the introduction of its new and ...
    ... androgen deprivation, official says , MONDAY, Feb. 1 ... the physicians who treat them are being warned ... the malignancy might increase the risk of heart ... substantial amount of data demonstrating that ADT adversely ...
    ... scored lowest on test also had worst outcomes, study reports, ... or thinking abilities could signal an increased likelihood for a ... men who were not diagnosed as having dementia but who ... greatly increased risk for stroke. , It,s not yet clear ...
    ... , Less serious recurrence seen with Ponseti casting method , ... in a thousand babies born in the United States , but ... feet compatible with an active, normal lifestyle. A new study in the ... Joint Surgery (JBJS) compared two common treatment options for clubfoot – ...
    ... , GREENWOOD VILLAGE, Colo. , Feb. ... revenue cycle solutions for the healthcare industry, announced today ... electronic EDI 278 transaction to UnitedHealthcare conforming to new ... UnitedHealthcare requests hospitals to submit EDI notification of each ...
    Cached Medicine News:Health News:Herbal Remedies Can Cause Cardiac Problems 2Health News:Herbal Remedies Can Cause Cardiac Problems 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 2Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 4Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:Poor Mental Functioning May Predict Stroke 2Health News:Poor Mental Functioning May Predict Stroke 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 2Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 4Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 2Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 3
    ... world-class clinician documentation and electronic medical record ... the specific needs of intensive care units ... deep clinical functionality has secured its place ... in critical care, and its the most ...
    ... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
    ... developed a touchscreen EHR and is scheduled ... user can choose to use a mouse, ... eye contact while recording encounter results. If ... also runs on a pen tablet that ...
    Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
    Medicine Products: